RISA Labs raises $11.1 million

RISA Labs has raised $11.1 million in a Series A round co-led by Cencora Ventures and Optum Ventures to expand deployment of its AI operating system across oncology practices, health systems, specialty pharmacies, and infusion networks.

The Palo Alto–based company automates patient access, benefits verification, and prior authorization, replacing manual oncology workflows with AI-driven processes that adapt in real time as payer rules and systems change. RISA reports rapid adoption among early customers, with some expanding into multiple workflows within months of initial deployment.

RISA says its platform is already live at large U.S. oncology practices, where it has reduced administrative workload, lowered denial rates, and significantly shortened authorization timelines.

“In our vision for oncology, there are two sides to every patient’s journey: getting them on the right therapy faster and deepening our understanding of the disease for the next patient through data” – Kshitij Jaggi, CEO of RISA Labs.

“As the treatments available for oncology patients increase in number and complexity, solutions to help streamline operational processes and enable efficient access to therapy become vital. We look forward to supporting RISA on their next phase of growth.” – Jason Dinger, Senior Vice President, Strategic Execution at Cencora.